A single-center retrospective analysis of 85 children and adolescents with limited-stage Hodgkin lymphoma
10.3760/cma.j.issn.0253-2727.2020.08.006
- VernacularTitle:85例儿童和青少年局限期霍奇金淋巴瘤临床分析
- Author:
Bin WU
1
;
Juan WANG
;
Jia ZHU
;
Zijun ZHEN
;
Suying LU
;
Feifei SUN
;
Junting HUANG
;
Xiaofei SUN
Author Information
1. 华南肿瘤学国家重点实验室，中山大学肿瘤防治中心儿童肿瘤科 510060；华中科技大学同济医学院附属武汉儿童医院血液肿瘤科 430016
- Keywords:
Hodgkin lymphoma;
Limited stage;
Chemotherapy;
Radiation;
Children and adolescents
- From:
Chinese Journal of Hematology
2020;41(8):649-654
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To summarize the efficiency and long-term outcomes of limited-stage Hodgkin lymphoma in children and adolescents with ABVD therapy and determined whether omitting radiotherapy for a low-risk patient enabled the achievement of complete response (CR) after chemotherapy.Methods:We retrospectively analyzed data from 13 y (2004-2016) from patients aged ≤18 y with limited-stage HL admitted to the Sun Yat-sen University Cancer Center. Patients received treatment with ABVD chemotherapy alone or ABVD chemotherapy followed by low-dose involved field radiotherapy.Results:Total 85 subjects were eligible for study inclusion; the median age was 12 (3-18) y; 66 (77.6%) were men, 80 (94.1%) had stage-II disease, 56 (65.9%) were at low-risk, and the median follow-up duration was 72 (8-196) months; 12 relapsed, 2 had secondary neoplasm, and 2 died. The 5-year event free survival (EFS) was (85.6±3.8) %, and the overall survival (OS) was 100%. The 5-year EFS and OS was (89.1±4.2) % and 100%, respectively, for the low-risk cohort and (79.3±7.5) % and 100%, respectively for the intermediate-risk cohort. Among the 39 low-risk patients who achieved CR after chemotherapy, 15 received treatment with chemotherapy followed by LD-IFRT. In the exploratory subset analysis, the low-risk cohort who achieved CR after chemotherapy, the 5-year EFS for comparing ABVD alone with chemotherapy followed by LD-IFRT was (87.0±7.0) % versus 100% ( P=0.506) , and the OS was 100% for both the groups. Conclusions:Our retrospective analysis showed excellent survival of limited-stage HL patients with ABVD therapy. For patients who achieving CR after chemotherapy with low-risk HL, received chemotherapy followed by LD-IFRT does not improve 5-year OS and EFS. The use of risk- and response-based stratification may facilitate the development of effective and less toxic protocols.
